Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy

• Status: Unknown status
• Trial end date: 2021-03-30
• Target enrollment: 0
• Participant gender: All

Summary

Guidelines recommended that patients with bioprosthetic heart valves (BHV) only need 6 months oral anticoagulation therapy after operation. However, a small part of patients still suffered thrombotic events after withdrawal of warfarin, which means these patients may need extend anticoagulation therapy. D-dimer, a sensitive marker of thrombosis or prethromboembolism state. Previous studies have demostrated that patients with elevated D-dimer levels have significant more clinical outcomes than those with nagative D-dimer levels. The aim of this study was to evaluate whether D-dimer could guide the duration of oral anticoagulation therapy in patients with BHV.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wuhan Asia Heart Hospital
• Treatments: Anticoagulants; Fibrin fragment D; Warfarin

Criteria

Inclusion Criteria:

• Patients received BHV within 3 months

Exclusion Criteria:

• Recently throboemblism within 6 months

• Recently bleedings within 3 months

• Evaluated lifetime less than 2 years